Journal of Leukocyte Biology eBioscience full spectrum cell analysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published online as doi:10.1189/jlb.0804460 on November 17, 2004

Published online before print November 17, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0804460v1
77/2/129    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yonekawa, K.
Right arrow Articles by Harlan, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yonekawa, K.
Right arrow Articles by Harlan, J. M.
(Journal of Leukocyte Biology. 2005;77:129-140.)
© 2005 by Society for Leukocyte Biology

Targeting leukocyte integrins in human diseases

Karyn Yonekawa* and John M. Harlan{dagger},1

* Division of Nephrology, Department of Pediatrics, and
{dagger} Division of Hematology, Department of Medicine, University of Washington, Seattle

1 Correspondence: Division of Hematology, Harborview Medical Center, Mailstop 359756, 325 Ninth Avenue, Seattle, WA 98115. E-mail: jharlan{at}u.washington.edu

As our understanding of integrins as multifunctional adhesion and signaling molecules has grown, so has their recognition as potential therapeutic targets in human diseases. Leukocyte integrins are of particular interest in this regard, as they are key molecules in immune-mediated and inflammatory processes and are thus critically involved in diverse clinical disorders, ranging from asthma to atherosclerosis. Antagonists that interfere with integrin-dependent leukocyte trafficking and/or post-trafficking events have shown efficacy in multiple preclinical models, but these have not always predicted success in subsequent clinical trials (e.g., ischemia-reperfusion disorders and transplantation). However, recent successes of integrin antagonists in psoriasis, inflammatory bowel disease, and multiple sclerosis demonstrate the tremendous potential of antiadhesion therapy directed at leukocyte integrins. This article will review the role of the leukocyte integrins in the inflammatory process, approaches to targeting leukocyte integrins and their ligands, and the results of completed clinical trials.

Key Words: adhesion • clinical • trials • inflammation




This article has been cited by other articles:


Home page
ScienceHome page
E. Y. Choi, E. Chavakis, M. A. Czabanka, H. F. Langer, L. Fraemohs, M. Economopoulou, R. K. Kundu, A. Orlandi, Y. Y. Zheng, D. A. Prieto, et al.
Del-1, an Endogenous Leukocyte-Endothelial Adhesion Inhibitor, Limits Inflammatory Cell Recruitment
Science, November 14, 2008; 322(5904): 1101 - 1104.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Miyazaki, M. Bunting, D. M. Stafforini, E. S. Harris, T. M. McIntyre, S. M. Prescott, V. S. Frutuoso, F. C. Amendoeira, D. de Oliveira Nascimento, A. Vieira-de-Abreu, et al.
Integrin {alpha}D 2 Is Dynamically Expressed by Inflamed Macrophages and Alters the Natural History of Lethal Systemic Infections
J. Immunol., January 1, 2008; 180(1): 590 - 600.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
A. Zarbock and K. Ley
Mechanisms and Consequences of Neutrophil Interaction with the Endothelium
Am. J. Pathol., January 1, 2008; 172(1): 1 - 7.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Kong, M. Scully, C. S. Shelley, and S. P. Colgan
Identification of Pur{alpha} as a New Hypoxia Response Factor Responsible for Coordinated Induction of the beta2 Integrin Family
J. Immunol., August 1, 2007; 179(3): 1934 - 1941.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. V. Priestley, L. M. Scott, T. Ulyanova, and T. Papayannopoulou
Lack of {alpha}4 integrin expression in stem cells restricts competitive function and self-renewal activity
Blood, April 1, 2006; 107(7): 2959 - 2967.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. S. Iyer, R. S. Agrawal, C. R. Thompson, S. Thompson, J. A. Barton, and D. J. Kusner
Phospholipase D1 Regulates Phagocyte Adhesion
J. Immunol., March 15, 2006; 176(6): 3686 - 3696.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S.-S. J. Sung, S. M. Fu, C. E. Rose Jr., F. Gaskin, S.-T. Ju, and S. R. Beaty
A Major Lung CD103 ({alpha}E)-beta7 Integrin-Positive Epithelial Dendritic Cell Population Expressing Langerin and Tight Junction Proteins
J. Immunol., February 15, 2006; 176(4): 2161 - 2172.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
C. A. Reichel, A. Khandoga, H.-J. Anders, D. Schlondorff, B. Luckow, and F. Krombach
Chemokine receptors Ccr1, Ccr2, and Ccr5 mediate neutrophil migration to postischemic tissue
J. Leukoc. Biol., January 1, 2006; 79(1): 114 - 122.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. P. Mizgerd
Mac-1 mediates migration to lymph nodes
Blood, November 1, 2005; 106(9): 2927 - 2928.
[Full Text] [PDF]


Home page
CirculationHome page
K. Y. Stokes and D. N. Granger
Gaining More From Gamma Globulins
Circulation, September 27, 2005; 112(13): 1918 - 1920.
[Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. N. Morrell, K. Matsushita, and C. J. Lowenstein
A Novel Inhibitor of N-Ethylmaleimide-Sensitive Factor Decreases Leukocyte Trafficking and Peritonitis
J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 155 - 161.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Society for Leukocyte Biology.